Bioelectronics Corp (BIEL)

[GhostCat]

FREDERICK, Md., May 15, 2012 /PRNewswire via COMTEX/ -- BioElectronicsCorporation (OTC-PINK: BIEL), the maker of disposable, inexpensive, drug-freetopical pain and healing devices, announces that the Therapeutic ProductsDirectorate, Medical Devices Bureau of Health Canada has issued a Class IILicense for the RecoveryRx(TM) Post-Surgical and Wound Care Recovery product.The license means that the product can be sold Over-the-Counter (OTC) in Canada.RecoveryRx uses pulsed electromagnetic field therapy to reduce pain andinflammation and promote healing of injured tissue.

"We are pleased that Health Canada has recognized both the safety andeffectiveness of RecoveryRx by issuing this Class II license. RecoveryRxprovides a convenient, non-invasive, safe and effective therapy to improvehealing and reduce pain without the use of dangerous and potentially addictivenarcotic medications," said Andrew Whelan, CEO of BioElectronics.

The market potential for RecoveryRx as a post-surgical recovery therapy issignificant. Clinically shown to improve healing, reduce the need for narcoticpain medications, reduce scarring and reduce wound breakage, the post-surgicalapplication of RecoveryRx will reduce overall post-surgical complication rates.RecoveryRx is an appropriate therapy for treating pain and inflammation afteroral, joint replacement, hernia repair, cosmetic and general surgeries. It isexpected that women who have had cesarean sections who wish to avoid narcoticuse in order to safely breast feed their infants will embrace the use of thetherapy.

Even more profound is RecoveryRx's potential impact on diabetic wound treatmentand prevention. According to the Canadian Diabetes Association there are morethan 9 million Canadians currently living with diabetes or pre-diabetes. It iswell known that foot ulcers and wounds are one of the most devastatingcomplications of diabetes. Case studies show that RecoveryRx is effective athealing chronic wounds, and unlike advanced wound therapies, it has a low costwhich means that it can be applied, not just to existing stalled wounds, but asa first choice therapy to preclude the degradation of a developing wound.Providing a minimum of 7 days of therapy, RecoveryRx can be easily andseamlessly incorporated into wound dressing protocols. It is certain that theuse of RecoveryRx will dramatically reduce costs and time to heal chronicwounds. Currently the Canadian Wound Association estimates the average time andexpense to heal a chronic wound to be 165 days and $10,376 per instance. "Welook forward to demonstrating to both the patients and the national health caresystem, and ultimately all Canadians, how our low cost RecoveryRx deviceprovides effective management and prevention of chronic wounds and willsignificantly reduce the substantial financial costs of wound treatment," said Andrew Whelan.

About BioElectronics CorporationBioElectronics is an award winning developer andmanufacturer of advanced medical devices. Its products are ActiPatch® Therapy,for over-the-counter treatment of back pain and other musculoskeletal ailments,the Allay(TM) Menstrual Cycle Pain Therapy, and RecoveryRx(TM) for surgicalprocedures and wound care. The unique therapy delivery system, using patentedtechnology, provides a cost-effective home care to reduce soft tissue pain andswelling.

For more information, please see www.bielcorp.com. Contact: E & E CommunicationsPaul Knopick(949) 707-5365

SOURCE: http://www.digitaljournal.com/pr/710652